Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes

被引：0
|
作者：
Junko Oya
Tomoko Nakagami
Yukiko Hasegawa
Yuichiro Kondo
Aki Katamine
Mika Shimizu
Ryo Kubota
Rika Suda
Tetsuya Babazono
机构：
[1] Tokyo Women’s Medical University School of Medicine,Division of Diabetology and Metabolism, Department of Internal Medicine
来源：
Diabetology International | 2024年 / 15卷
关键词：
Type 2 diabetes; Insulin degludec/liraglutide; Insulin degludec/insulin aspart; HbA1c;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：237 / 243
页数：6
相关论文
共 50 条
  • [21] A SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE U100 AND INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN
    Zhou, L.
    Zhou, N.
    Hu, M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S386 - S386
  • [22] Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
    Heo, Young-A
    [J]. DRUGS & THERAPY PERSPECTIVES, 2020, 36 (06) : 219 - 229
  • [23] Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
    Young-A Heo
    [J]. Drugs & Therapy Perspectives, 2020, 36 : 219 - 229
  • [24] Fixed Combination of Insulin Degludec and Liraglutide in Type 2 Diabetes Treatment
    Jaecke, E.
    Wilhelm, B.
    Kaiser, M.
    [J]. DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (06): : 387 - 395
  • [25] Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1529): : 147 - 149
  • [26] Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Niu, Yan-Li
    Zhang, Ye
    Song, Zhi-Yong
    Zhao, Chuan-Zhi
    Luo, Yun
    Wang, Yan
    Yuan, Jing
    [J]. IRANIAN JOURNAL OF PUBLIC HEALTH, 2024, 53 (02) : 313 - 322
  • [27] A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
    Mathieu, C.
    Rodbard, H. W.
    Cariou, B.
    Handelsman, Y.
    Philis-Tsimikas, A.
    Francisco, A. M. Ocampo
    Rana, A.
    Zinman, B.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (07): : 636 - 644
  • [28] Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus
    Atkin, Stephen
    Javed, Zeeshan
    Fulcher, Gregory
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (06) : 375 - 388
  • [29] Insulin degludec in clinical practice: type 1 diabetes patients switched from their basal insulin to insulin degludec
    Blanquez Martinez, David
    Hayon Ponce, Maria
    Caballero Romero, Alvaro
    Diaz Villamarin, Xando
    Nieto Gomez, Pelayo
    Moron Romero, Rocio
    Davila Fajardo, Cristina
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 301 - 302
  • [30] Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
    Jammah, Anwar Ali
    [J]. PRIMARY CARE DIABETES, 2021, 15 (01) : 132 - 137
12345